# US 2022/0031607 A1 · Injection composition containing fab i inhibitor, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031607 A1
- Document ID: US20220031607A1
- Status: Published application
- Kind: A1
- Application number: 17/296,355
- Filed: 2020-01-21
- Published: 2022-02-03
- Earliest claimed: 2019-01-21
- Assignees: CrystalGenomics, Inc.
- Applicants: Crystalgenomics, Inc.
- Inventors: Jae Pyoung CHO; Joong Myung CHO
- Web page: https://patentgrep.com/patent/US20220031607A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 31/04: Antibacterial agents
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for intravenous administration, containing a Fab I inhibitor, and a preparation method therefor. The present invention can be effectively applied to an infection caused by antibiotic-resistant bacteria. Specifically, the present invention enables treatment effects to be more rapidly initiated by improving solubility and dissolution rate, and enables bioavailability to be improved. In addition, by controlling the size of particles, mixing and content uniformity of a preparation can be improved.

## Claims

### Claim 1

A composition for injection comprising:
1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof; and
a polymer compound, a solubilizing agent, or a mixture thereof.

### Claim 2 (depends on 1)

The composition for injection according to claim 1, wherein based on the total weight of the composition, the content of 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof is 0.1 to 10% by weight, the content of the polymer compound is 5 to 40% by weight, and the content of the solubilizing agent is 10 to 30% by weight.

### Claim 3 (depends on 1)

The composition for injection according to claim 1, wherein the polymer compound comprises one or more selected from the group consisting of dextrin, cyclodextrin, poloxamer, dextran, pectin, pectin derivatives, alginate, starch, hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, hydroxylethylcellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose acetate succinate, hydroxylethylmethyl cellulose, guar gum, locust bean gum, tragacantha, carrageenan, acacia gum, arabic gum, gellan gum, xanthan gum, gelatin, casein, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl acetaldiethyl aminoacetate, poly(butylmethacrylate, (2-dimethylaminoethyl)methacrylate, methylmethacrylate) copolymer, polyethylene glycol, polyethylene oxide and carbomer.

### Claim 4 (depends on 1)

The composition for injection according to claim 1, wherein the solubilizing agent comprises one or more selected from the group consisting of propylene glycol, polyethylene glycol, dipropylene glycol, diethylene glycol, diethylene glycol monoethyl ether, glycerol, Tween 80, cremophor and transcutol.

### Claim 5 (depends on 1)

The composition for injection according to claim 1, wherein the composition is in the form of a liquid, emulsion or lyophilized powder.

### Claim 6

A method of preparing a composition for injection comprising 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof, the method comprising:
adding 4-benzyloxy-1H-pyridone, 2-methyl-3-nitro-benzylchloride and potassium tert-butoxide to dimethylformamide and mixing and reacting them under heating;
reacting the mixture, adding purified water and drying under heating;
dissolving the dried product in an organic solvent and adding purified water for layer separation;
recovering the organic layer, filtering and concentrating to prepare a concentrate;
reconcentrating the concentrate and adding hexane to prepare an intermediate precipitate;
dissolving the obtained precipitate, cooling, filtering and drying to obtain a dried product; and
dissolving the obtained dried product in an organic solvent and then adding and reacting iron chloride hexahydrate, activated carbon and hydrazine monohydrate, cooling and filtering to obtain a final precipitate, and drying and pulverizing the obtained final precipitate to prepare the compound.

### Claim 7 (depends on 6)

The method of preparing a composition for injection according to claim 6, wherein the method further comprises adding an acidic substance.

### Claim 8 (depends on 7)

The method of preparing a composition for injection according to claim 7, wherein the acidic substance comprise one or more selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, oxalic acid, fumaric acid, malonic acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid and EDTA.

### Claim 9 (depends on 6)

The method of preparing a composition for injection according to claim 6, wherein the method further comprises:
1) dissolving a polymer compound and 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof in a solvent; and
2) vacuum drying the solution of 1) and then micronizing the resulting solid.

### Claim 10 (depends on 6)

The method of preparing a composition for injection according to claim 6, wherein the method further comprises:
1) dissolving a polymer compound and a lipid-based surfactant and 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof in a solvent;
2) gradually adding a solubilizing agent to the solution of 1); and
3) centrifugating and vacuum drying the solution of 3) and then homogenizing it.

### Claim 11 (depends on 10)

The method of preparing a composition for injection according to claim 10, wherein the lipid-based surfactant includes soybean oil.

### Claim 12 (depends on 6)

The method of preparing a composition for injection according to claim 6, wherein the composition is prepared in the form of a solid dispersion, a liposome formulation, or a combination thereof.

### Claim 13 (depends on 1)

The method of preparing a composition for injection according to claim 1, wherein the composition is for the treatment of bacterial infections.
